BioCentury on BioBusiness,
Table: 4Q setbacks
Back to the parent article
Monday, January 7, 2013
Selected fourth quarter
clinical and regulatory setbacks.
Science S.A. (Euronext:AB)
plus Gemzar gemcitabine from Eli Lilly and Co. (NYSE:LLY) fails in a
Phase III trial to treat pancreatic cancer
Therapeutics Inc. (TSX:NPC)
administered as a nasal spray fails a Phase II/III trial to treat progressive
Therapeutics Inc. (NASDAQ:FOLD)/GlaxoSmithKline
plc (LSE:GSK; NYSE:GSK)
fails the Phase III FACETS (Study 011) trial to treat Fabry's disease
Inc./Geron Corp. (NASDAQ:GERN)
development of GRN1005 after the compound produced no confirmed intracranial
responses in the Phase II GRABM-B trial to treat brain metastases arising
from metastatic breast cancer
Pharmaceuticals Inc. (NASDAQ:ARIA)/Merck
& Co. Inc. (NYSE:MRK)
MAA for ridaforolimus as maintenance therapy for patients with soft tissue
sarcoma or primary malignant bone tumor
Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568)/Kyowa Hakko Kirin Co. Ltd.
Phase III MARQUEE trial to treat NSCLC after analysis shows tivantinib plus
Tarceva erlotinib will miss the primary endpoint; later in the quarter the
partners discontinue the Asian Phase III ATTENTION trial of tivantinib in
NSCLC based on a recommendation by the trial's safety committee
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]